<DOC>
	<DOCNO>NCT00117975</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody , rituximab galiximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving one monoclonal antibody may better way block cancer growth . PURPOSE : This phase II trial study well give rituximab together galiximab work treat patient stage II , stage III , stage IV non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Rituximab Galiximab Treating Patients With Stage II , Stage III , Stage IV Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine overall complete response rate patient previously untreated CD20-positive bulky stage II stage III IV follicular non-Hodgkin 's lymphoma treat rituximab galiximab . - Determine time disease progression patient treat regimen . Secondary - Determine toxicity profile regimen patient . - Correlate Fc receptor polymorphism profile response patient treat regimen . OUTLINE : This multicenter study . - Induction therapy ( month 1 ) : Patients receive rituximab IV day 1 , 8 , 15 , 22 galiximab IV 1 hour day 3 , 8 , 15 , 22 . - Extended induction therapy ( month 3 , 5 , 7 , 9 ) : Beginning month 3 , patient receive rituximab galiximab day 1 . Treatment repeat every 56 day 4 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 4 month 10 year . PROJECTED ACCRUAL : A total 51 patient accrue study within 18 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Documentation Disease 1.1 Previously untreated , histologically confirm follicular lymphoma , WHO classification , grade 1 , 2 , 3a ( &gt; 15 centroblasts per high power field centrocytes present ) stage III , IV , bulky ( i.e. , single mass ≥ 7 cm unidimensional measurement ) stage II . 1.1.1 Bone marrow biopsy sole mean diagnosis acceptable , may submit conjunction nodal biopsy . Fine needle aspirate acceptable . 1.1.2 Failure submit pathology specimen within 60 day patient registration result patient declare ineligible . 1.2 Institutional flow cytometry immunohistochemistry must confirm CD20 antigen expression . 1.3 Patients classified high risk accord Follicular Lymphoma International Prognostic Index ( FLIPI ) consider CALGB 50102/SWOG S0016 ( A Phase III Trial CHOP v CHOP + Rituximab v CHOP + Iodine131Labeled Monoclonal AntiB1 Antibody [ Tositumomab ] For Treatment Newly Diagnosed Follicular NonHodgkin 's Lymphomas ) . 2 . Prior Treatment 2.1 No prior therapy nonHodgkin lymphoma include chemotherapy , radiation immunotherapy ( e.g. , monoclonal antibodybased therapy ) 2.2 No corticosteroid within two week prior study , except maintenance therapy nonmalignant disease 3 . Age Patients must ≥ 18 year age 4 . ECOG Performance Status Patients must ECOG Performance Status 02 . 5 . Measurable Disease Measurable disease must present either physical examination image study . 5.1 Nonmeasurable disease alone acceptable . 5.2 Any tumor mass &gt; 1 cm acceptable . 5.3 Lesions consider nonmeasurable include follow : Bone lesion ( lesion present note ) Ascites Pleural/pericardial effusion Lymphangitis cutis/pulmonis Bone marrow ( involvement nonHodgkin lymphoma note ) . 6 . CNS Involvement Patients must know CNS involvement lymphoma . 7 . HIV Infection Patients must know HIV infection . 7.1 Patients history intravenous drug abuse behavior associate increase risk HIV infection test exposure HIV virus . 7.2 Patients test positive know infected eligible due increase risk infection regimen . An HIV test require entry protocol , require patient perceive risk . 8 . Human AntiChimeric Antibody Patients must know baseline human antichimeric antibody ( HACA ) positivity . 9 . Pregnancy Nursing Status Patients must nonpregnant nonnursing . 9.1 Due unknown teratogenic potential galiximab , pregnant nursing patient may enrol . 9.2 Women men reproductive potential agree use effective mean birth control throughout participation study . 9.3 Appropriate method birth control include oral contraceptive , implantable hormonal contraceptive , double barrier method ( diaphragm plus condom ) . 10 . Second Malignancy Patients `` currently active '' second malignancy , nonmelanoma skin cancer eligible . 10.1 This include Waldenstrom 's Macroglobulinemia , since patient experienced transient increase IgM follow initiation rituximab , potential hyperviscosity syndrome require plasmapheresis . 10.2 Patients consider `` currently active '' malignancy complete anticancer therapy , consider physician less 30 % risk relapse . 11 . Required Initial Laboratory Values : ANC ≥ 1000/µL Platelet Count ≥ 50,000/µL Creatinine ≤ 2 x ULN Unless attributable lymphoma Total Bilirubin ≤ 2 x ULN*† Unless attributable Gilbert 's disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
</DOC>